Choosing an angiotensin-receptor blocker: Blood pressure lowering, cardiovascular protection or both?

Future Cardiology

Volumn 6, Issue 1, 2010, Pages 129-135

  Neldam, Steen ^a  

^a Rodovre Centrum 294   (Denmark)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Antihypertensive; Blood pressure; Cardiovascular protection; Target organ

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG CHOICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; LOSARTAN; RAMIPRIL; RISK FACTORS; TETRAZOLES;

EID: 73949091078     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.09.61     Document Type: Review

References (41)

1. Kearney PM, Whelton M, Reynolds K et al.: Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
2. Chobanian AV, Bakris GL, Black HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289, 2560-2572 (2003).
3. Kotseva K, Wood D, De Backer G et al.: EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur. J. Cardiovasc. Prev. Rehabil. 16, 121-137 (2009).
4. Weycker D, Edelsberg J, Vincze G et al.: Blood pressure control in patients initiating antihypertensive therapy. Ann. Pharmacother. 42, 169-176 (2008).
5. Williams B, Lacourciere Y, Schumacher H, Gosse P, Neutel JM: Antihypertensive efficacy of telmisartan vs ramipril over the 24 h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J. Hum. Hypertens 23(9), 610-619 (2009).
6. Corrao G, Zambon A, Parodi A et al.: Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J. Hypertens 26, 819-824 (2008).
7. Song JC, White CM: Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 36, 487-499 (2001).
8. Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H: Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 9, 203-210 (2004).
9. Oparil S, Guthrie R, Lewin AJ et al.: An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clin. Ther. 20, 398-409 (1998).
10. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J: Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J. Clin. Hypertens. (Greenwich) 3, 283-291, 318 (2001).
11. Carson P, Giles T, Higginbotham M et al.: Angiotensin receptor blockers: evidence for preserving target organs. Clin. Cardiol. 24, 183-190 (2001).
12. Iwanami J, Mogi M, Iwai M, Horiuchi M: Inhibition of the renin-angiotensin system and target organ protection. Hypertens. Res. 32, 229-237 (2009).
13. Atlas SA: The renin-angiotensin-aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm. 13, 9-20 (2007).
14. Volpe M, Ruilope LM, McInnes GT, Waeber B, Weber MA: Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J. Hum. Hypertens. 19, 331-339 (2005).
15. Kidney Disease Outcomes Quality Initiative (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 43, S1-S290 (2004).
16. Mancia G, De Backer G, Dominiczak A et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105-1187 (2007). (Pubitemid 46924065)
17. de Zeeuw D, Remuzzi G, Parving HH et al.: Albuminuria, a therapeutic target for cardiovascular protection in Type 2 diabetic patients with nephropathy. Circulation 110, 921-927 (2004). (Pubitemid 39128617)
18. Pohl MA, Blumenthal S, Cordonnier DJ et al.: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J. Am. Soc. Nephrol. 16, 3027-3037 (2005).
19. Parving HH, Lehnert H, Bröchner- Mortensen J et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. 345, 870-878 (2001). (Pubitemid 34940826)
20. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106, 672-678 (2002).
21. Chrysant SG: Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared with angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J. Hum. Hypertens. 19, 923-931 (2005).
22. Dahlof B, Devereux RB, Kjeldsen SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002). (Pubitemid 34286536)
23. Papademetriou V, Farsang C, Elmfeldt D et al.: Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol. 44, 1175-1180 (2004).
24. Schrader J, Luders S, Kulschewski A et al.: Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36, 1218-1226 (2005).
25. Bakris G, Burgess E, Weir M, Davidai G, Koval S: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 74, 364-369 (2008).
26. Julius S, Kjeldsen SE, Weber M et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022-2031 (2004).
27. Yusuf S, Teo KK, Pogue J et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
28. Yusuf S, Sleight P, Pogue J et al.: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
29. Yusuf S, Teo K, Anderson C et al.: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372, 1174-1183 (2008).
30. Pitt B, Poole-Wilson P, Segal R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355, 1582-1587 (2000).
31. Cohn JN, Tognoni G; for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
32. Pfeffer MA, Swedberg K, Granger CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759-766 (2003). (Pubitemid 37093915)
33. Dickstein K, Kjekshus J; and the OPTIMAAL Steering Committee; for the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360, 752-760 (2002).
34. Pfeffer MA, McMurray JJ, Velazquez EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893-1906 (2003).
35. Neldam S: Telmisartan/hydrochlorothiazide in the treatment of hypertension. Aging Health 2, 395-408 (2006).
36. Neldam S, Edwards C: Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension. J. Clin. Hypertens. (Greenwich) 10, 612-618 (2008).
37. Littlejohn TW, III, Majul CR, Olvera R et al.: Results of treatment with telmisartan-amlodipine in hypertensive patients. J. Clin. Hypertens. (Greenwich) 11, 207-213 (2009).
38. Bomback AS, Toto R: Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am J. Hypertens 22, 1032-1040 (2009).
39. Solomon SD, Appelbaum E, Manning WJ et al.: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119, 530-537 (2009).
40. McMurray JJ, Pitt B, Latini R et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17-24 (2008).
41. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).